UB-421 not checked

UBP Greater China (Shanghai) Co., Ltd · United BioPharma · dB4C7 mAb

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
9 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.”In the company’s words, NCT04985890 on ClinicalTrials.gov
Tested for
HIV-1-infection
Main trialPhase 2
“* To assess the impact of UB-421 and chidamide in changing HIV-1 viral reservoir profile among HIV-1 suppressed patients who undergo short-term ART interruption. * To evaluate the safety and tolerability of UB-421 combined with chidamide among HIV-1 suppressed patients who undergo short-term ART interruption.”In the company’s words, NCT04985890 on ClinicalTrials.gov
Other names
dB4C7 mAb

Other drugs for HIV-1-infection

All 24 drugs for HIV-1-infection

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Dec 2026 A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir
Phase 3Withdrawn 31 Dec 2025 To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults
Phase 3Unknown 30 Jun 2026 UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
Phase 2Completed 15 Oct 2020 The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
Phase 2Completed 1 Feb 2023 A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
Phase 2Unknown Mar 2024 UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients
Phase 2Unknown 30 Jun 2024 The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
Phase 1Completed 25 May 2022 Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
Phase 1Unknown 31 Dec 2025 Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow UB-421

Following is part of Solo: you see every change to UB-421 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in